Pomerantz Law Firm Investigates argenx SE Following Discontinuation of Phase 3 Sjögren's Disease Study
Pomerantz LLP has launched an investigation into argenx SE (NASDAQ: ARGX) to determine if the company or its executives engaged in securities fraud. The probe follows the company's October 8, 2026, announcement that it would discontinue the Phase 3 UNITY study of efgartigimod subcutaneous for adults with moderate-to-severe Sjögren's disease. The decision to halt the trial was based on a recommendation from an Independent Data Monitoring Committee (IDMC) after an interim analysis concluded the study could not meet its primary endpoint due to futility. Following this announcement, argenx SE shares experienced significant volatility, dropping 11.83% to close at $818.63 per share.
Tickers: $ARGX
Topics: Class Action Investigation Clinical Trial Failure Securities Fraud Stock Price Drop
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures (9 articles)